@article{27c215d6961a4d3c9e55bdd9d237eea6,
title = "Lessons from next-generation sequencing analysis in hematological malignancies",
abstract = "Next-generation sequencing has led to a revolution in the study of hematological malignancies with a substantial number of publications and discoveries in the last few years. Significant discoveries associated with disease diagnosis, risk stratification, clonal evolution and therapeutic intervention have been generated by this powerful technology. As part of the post-genomic era, sequencing analysis will likely become part of routine clinical testing and the challenge will ultimately be successfully transitioning from gene discovery to preventive and therapeutic intervention as part of individualized medicine strategies. In this report, we review recent advances in the understanding of hematological malignancies derived through genome-wide sequence analysis.",
keywords = "Clonal architecture, Genome sequencing, Hematological malignancy, RNA sequencing",
author = "E. Braggio and Egan, {J. B.} and R. Fonseca and Stewart, {A. K.}",
note = "Funding Information: RF has received a patent for the prognostication of MM based on genetic categorization of the disease. He has received consulting fees from Medtronic, Otsuka, Celgene, Genzyme, BMS, Lilly, Millenium and AMGEN. He also has sponsored research from Cylene and Onyx. EB is a recipient of the Marriott Specialized Workforce Development awards in Individualized Medicine, The Henry Predolin Foundation Career Development award and the George Haub Family Career Development award fund in Cancer Research. JBE is a recipient of the Multiple Myeloma Research Foundation Research Fellow award. The remaining authors declare no conflict of interest. Funding Information: This work was supported by NIH Grant CA133115-01 and Mayo Clinic Cancer Center. Rafael Fonseca is a Clinical Investigator of the Damon Runyon Cancer Research Fund. His work is supported by Grants SPORE CA90297052, P01 CA62242, R01 CA83724, ECOG CA 21115T, Predolin Foundation, Mayo Clinic Cancer Center and the Mayo Foundation.",
year = "2013",
month = jul,
doi = "10.1038/bcj.2013.26",
language = "English (US)",
volume = "3",
journal = "Blood cancer journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "7",
}